Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ERN1 | O75460 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400790 | 1.00 | TACR1 (0.44) | TACR1ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL6406585 | 1.00 | TACR1 (0.44) | TACR1ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL6402101 | 0.87 | ALDH1A1 (0.42) | TACR1ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL7247609 | 0.87 | ALDH1A1 (0.42) | TACR1ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL6401662 | 0.75 | ALDH1A1 (0.43) | TACR1ALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL7295409 | 0.73 | ALDH1A1 (0.49) | ALDH1A1GAASMN1; SMN2LMNAHPGD | |
| SCHEMBL6400531 | 0.72 | PDK2 (0.43) | TACR1ALDH1A1ESR1 | |
| SCHEMBL6400509 | 0.72 | PDK2 (0.43) | TACR1ALDH1A1ESR1 | |
| SCHEMBL6406622 | 0.72 | PDK2 (0.43) | TACR1ALDH1A1ESR1 | |
| SCHEMBL7530892 | 0.72 | ALDH1A1 (0.41) | ALDH1A1GAASMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | claimed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | claimed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | claimed |
| EP-1032571-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | claimed |
| US-20050234275-A1 | Reduction of naphthalene concentration in aromatic fluids | EXXONMOBIL CHEMICAL PATENTS INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2004094566-A1 | REDUCTION OF NAPHTHALENE CONTENT IN HYDROCARBON FLUIDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1032571-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | TACR1 2/4885ALDH1A1 571/4885GAA 2919/4885 |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | TACR1, HRH2, GRPR | TACR1 1/4885ALDH1A1 308/4885GAA 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.